Company news

PTC Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients

November 25, 2024

PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy

November 12, 2024

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 6, 2024

PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission

October 29, 2024

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results

October 23, 2024

CHMP Maintains Negative Opinion on Translarna™ Reexamination

October 17, 2024

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results

October 13, 2024

PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

October 7, 2024

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

September 30, 2024

FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program

September 25, 2024

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

August 7, 2024

PTC Therapeutics Announces Sepiapterin NDA Submission to FDA

July 29, 2024

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results

July 24, 2024

CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review

June 27, 2024

Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients

June 19, 2024

PTC Therapeutics to Participate at Upcoming Investor Conference

May 28, 2024

PTC Therapeutics Announces Validation of Sepiapterin European MAA

May 27, 2024

PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation

May 19, 2024

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™

May 13, 2024

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

April 24, 2024

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results

April 10, 2024

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

March 27, 2024

PTC Therapeutics Provides Key Regulatory Updates

March 18, 2024

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

February 28, 2024

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

February 14, 2024

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure

January 24, 2024

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference

January 7, 2024

PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities

December 4, 2023

PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results

October 25, 2023

PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion

October 18, 2023

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results

October 15, 2023

PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce

September 27, 2023

CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization

September 14, 2023

PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community

September 6, 2023

PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium

August 27, 2023

PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results

August 2, 2023

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results

July 19, 2023

PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize

July 18, 2023

PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer

July 16, 2023

PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin

July 10, 2023

PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

June 28, 2023

PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients

June 20, 2023

PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial

May 22, 2023

PTC Therapeutics Announces Strategic Pipeline Prioritization

May 22, 2023

PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients

May 16, 2023

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

April 27, 2023

PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results

April 26, 2023

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results

April 12, 2023

Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics

March 23, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 33 decks. Every deck is listed under its year.